These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 19954276)
1. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Tolman JA; Faulkner MA Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276 [TBL] [Abstract][Full Text] [Related]
2. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827 [TBL] [Abstract][Full Text] [Related]
6. Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Pellock JM Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183 [TBL] [Abstract][Full Text] [Related]
7. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Sergott RC; Westall CA Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180 [TBL] [Abstract][Full Text] [Related]
9. Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects. Besag FM Curr Drug Saf; 2010 Jul; 5(3):188-90. PubMed ID: 20624131 [No Abstract] [Full Text] [Related]
10. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Wohlrab G; Leiba H; Kästle R; Ramelli G; Schmitt-Mechelke T; Schmitt B; Landau K Epilepsia; 2009 Aug; 50(8):2006-8. PubMed ID: 19682036 [No Abstract] [Full Text] [Related]
11. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Carmant L Acta Neurol Scand Suppl; 2011; (192):36-47. PubMed ID: 22061179 [TBL] [Abstract][Full Text] [Related]
12. Visual field constriction on vigabatrin. Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799 [TBL] [Abstract][Full Text] [Related]
13. Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life? Riikonen R Epilepsia; 2009 Aug; 50(8):2005-6. PubMed ID: 19682035 [No Abstract] [Full Text] [Related]
14. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Wheless JW; Carmant L; Bebin M; Conry JA; Chiron C; Elterman RD; Frost M; Paolicchi JM; Donald Shields W; Thiele EA; Zupanc ML; Collins SD Epilepsia; 2009 Feb; 50(2):195-205. PubMed ID: 19054414 [TBL] [Abstract][Full Text] [Related]
15. Drug approved to treat infantile spasms. Thompson CA Am J Health Syst Pharm; 2009 Oct; 66(19):1682. PubMed ID: 19767370 [No Abstract] [Full Text] [Related]
17. Vigabatrin administration in patients with infantile spasms: the risks. Jaseja H Clin Neurol Neurosurg; 2010 Nov; 112(9):835. PubMed ID: 20934097 [No Abstract] [Full Text] [Related]
18. Visual field constriction is not limited to children treated with vigabatrin. Wohlrab G; Boltshauser E; Schmitt B; Schriever S; Landau K Neuropediatrics; 1999 Jun; 30(3):130-2. PubMed ID: 10480207 [TBL] [Abstract][Full Text] [Related]
19. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Miller NR; Johnson MA; Paul SR; Girkin CA; Perry JD; Endres M; Krauss GL Neurology; 1999 Dec; 53(9):2082-7. PubMed ID: 10599785 [TBL] [Abstract][Full Text] [Related]
20. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Camposano SE; Major P; Halpern E; Thiele EA Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]